About Our Company
Biological Dynamics, Inc. is a leader in exosome-isolation technology. We are committed to improving global health outcomes by enabling tests that better detect a range of conditions, including early stage cancer, treatment response, and cancer recurrence. Using exosomes, these test can provide higher sensitivity than competing approaches. Our ExoVerita™ Pro platform revolutionizes exosomes and extracellular vesicle isolation by enabling a simple, reliable, and automated workflow to enrich for exosomes, powering scalable clinical tests for us and our customers to address some of the most challenging diseases.
Our Mission
Delivering unique innovations to understand diseases and save lives.
Executive Team
Dr. Billings has devoted his life to studying and teaching medicine and genetics, while accelerating the use of a broad range of novel genomic technologies in clinical settings. Over his decades in healthcare, he has established key business partnerships, driving adoption of innovative discoveries and commercial success. His leadership is backed by notable achievements—physician, researcher, founder, senior executive or director of multiple public and private companies, and scientific advisor for government entities.
Dr. Billings has held academic appointments at Harvard University, U.C. San Francisco, Stanford University, and U.C. Berkeley; and served as a board-certified internist and medical geneticist at leading medical centers. His published doctoral studies at Harvard were supervised by Dr. Baruj Benacerraf who subsequently received the Nobel Prize in Medicine. In addition, he has served on the Scientific Advisory Board of the Food and Drug Administration (FDA), the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and as an appointee to the Secretary’s Advisory Committee on Genetics, Health, and Society at the Department of Health and Human Services. Previously, he has been Chief Medical Officer or Senior Physician at Laboratory Corporation of America Holdings, Life Technologies Corp, Thermo Fisher Scientific Inc., and Natera, Inc.
He holds an MD and a PhD in Immunology from Harvard, and an Artium Baccalaureus, summa cum laude from U.C. San Diego.
Paul R. Billings, MD, PhD, FACP, FACMGG – CEO and Director
Mr. Aicher is currently Executive Chairman of Roswell Biotechnologies, a molecular electronics company, digitizing biology with molecular electronics to elucidate, diagnose and treat disease, is a Founder of Alveo Technologies, a company focused on solving global health challenges, an Executive Director at Genetic Signatures (ASX: GSS), a company providing innovative molecular diagnostics solutions, is Chairman of CytoBay, a company developing novel oncology solutions and serves on the Board of Directors for Techcyte, a company providing Artificial Intelligence powered diagnostic solutions.
Mr. Aicher previously served on the Board of Fabric Genomics, which analyses and interprets genomic information, and was a Board member of Ariosa, a prenatal testing molecular diagnostics company until its acquisition by Roche in 2015. He co-founded and served as National Genetics Institute's (NGI) CEO from 1991 to 2012. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NYSE: LH) in 2000, where he ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue.
He holds a Bachelor of Science in Business Administration from the University of Redlands and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young's "Entrepreneur of the Year" award for emerging technologies.
Mike Aicher – COO
Mr. Wulff joined Biological Dynamics in 2023 has over 35 years of financial management experience in both public and privately held companies in emerging growth life sciences. He most recently served as Chief Financial Officer at JenaValve Technology, where he played an instrumental role in the corporate relocation from Germany and subsequent growth of its US operations. In addition, he managed the closing of various capital raise transactions, including equity, debt and international out-licensing of intellectual property. Prior to JenaValve, Peter served as the financial corporate officer for medical technology companies such as Alphatec Spine Holdings, Artes Medical, CryoCor, and Pure Biosciences.
Mr. Wulff has deep experience in growth and risk management for late-stage development companies launching its commercial operations, in the US or Europe. He also managed turnarounds to shift to focused strategic initiatives driving for market approvals and adoption yielding either positive earnings or reducing cash burn. He has worked extensively in building both US-based business and subsidiaries in Europe, including manufacturing and distribution operations, as well as, executing business development initiatives with other business partners.
He holds an M.B.A. in Finance and a Bachelor of Arts degree in Economics and Germanic Languages, each from Indiana University.
Peter Wulff - CFO
Mr. Nall joined Biological Dynamics in 2022 and has been a leader in Healthcare and Biotech for over 30 years. Most recently he served as the President, CEO and Board Member at Biocept, a publicly traded cancer diagnostics company, where he led the company’s transition from Research and Development to full Commercialization. Prior to Biocept, he was General Manager – North America, at Clarient, a GE Healthcare Company, leading all aspects of Commercial Operations. He joined Clarient when it was an independent startup, helping grow the company to over $100 million in annual revenue, leading to the GE acquisition. Other companies Mr. Nall has held leadership roles with include Impath, Maquet Surgical, Columbia Vital Systems and American Cyanamid Davis and Geck Surgical.
He has served on the boards of Nonigenex, a company focused on Maternal Fetal Health; Alacrity, an LA based digital health company; and Clearity Foundation, a non-profit dedicated to supporting women who have been diagnosed with Ovarian Cancer. He also serves on the Industry Relations Committee for the Moores Cancer Center.
He holds a Bachelor of Science in Business Administration from the University of Central Missouri.
Mike Nall – CCO
Ms. Wickens has 20 years of executive leadership experience building Human Resources (HR) organizations for small-to-medium sized companies—from inception through acquisition. Prior to joining Biological Dynamics, Janet was VP of HR at Navican, Inc. contributing to a successful company launch and transition to Intermountain Healthcare. During the 2016 acquisition of Raintree Oncology to Cardinal Health, Janet led all HR M&A activities. She spent 10 years in successive HR leaderships positions at ID Analytics, creating the HR infrastructure from the ground up culminating in a successful acquisition by LifeLock.
Ms. Wickens holds a Bachelor of Science in Business Administration from the University of Great Falls and is a graduate of the UCSD HR Leadership program. In addition, she has been an active member of the Society for Human Resources Management since 2003.
Janet Wickens – CPO
Senior Leadership
A seasoned executive in the life sciences industry, Mr. Panza has helped growth-stage companies deliver scalable and sustained commercial success and select and execute on strategic partnerships, including $25B in transactions, in his 20-year career.
Mr. Panza has served as Head of Corporate Development & Legal at Roswell Biotechnologies, an ‘omics on chip’ biotech based in San Diego; Executive Vice President - Corporate Development and General Counsel at Accumen, Inc., a leading healthcare operations company (through its acquisition by Arsenal Capital Partners in 2019); Head of Corporate Legal at the medical device company, NuVasive; and Senior Corporate Counsel of Governance, Securities and M&A at LIFE Technologies (through its acquisition by Thermo Fisher Scientific). Jarrod has also served as a Strategic Business advisor to the Hydrafacial Company (through its IPO in 2021) and for Mesa Biotech, helping lead its integration into Thermo Fisher Scientific.
Jarrod Panza, JD - EVP, Corporate Development and Legal
Dr. Dhani is a surgeon scientist who completed his medical degree from St. George’s University, with a general surgery residency and transplant and hepato-pancreato-biliary (HPB) surgery residence at Georgetown University. He has an accomplished track record in studying liver disease, intestinal disease, and oncology-transplantation. Most notably, he has published and received awards for his work to elucidate markers of allograft rejection, including Emerging Livers Scholar Award from the American Association for the Study of Liver Disease and the Young Investigator Award from American Transplant Congress. He holds a Master’s in Clinical Research from UCSD, and is currently earning his MBA at Georgetown University. He previously held positions in the oncology division at Natera.
Harmeet Dhani, MD – Medical Director
Dr. Hinestrosa leads the research team in their efforts to develop the Verita™ platform, including the discovery of new applications and biomarkers implementing AC Electrokinetics. JP has been instrumental in the development Biological Dynamics’ biochip, drastically improving its efficiency and performance. In addition, he has demonstrated the capability of AC Electrokinetics to identify cell-free DNA, exosomes, RNA, and proteins.
Prior to joining Biological Dynamics, Dr. Hinestrosa completed postdoctoral assignments for the United States Department of Energy’s Oak Ridge National Laboratory and the École Polytechnique Fédérale de Lausanne in Switzerland, where he focused on the integration of chemistry, biology, and materials science for the generation of biochips. JP has authored numerous publications in the fields of biocompatible surfaces, nanofabrication, and self-assembled polymers. He holds a PhD in Chemical & Biomolecular Engineering from Clemson University and a BS in Chemical Engineering from Universidad Del Valle (Cali, Colombia).
Juan Pablo “JP” Hinestrosa, PhD – VP, Research
Mr. Turner leads the product development team in the engineering, design, and development of Biological Dynamics’ products—including instrumentation hardware & software, data infrastructure, consumables, industrial design and usability engineering. Rob has led the design and development of numerous devices implementing AC Electrokinetics technology, most notably the NanoVerita™—Biological Dynamics’ first CE marked instrument; the OmniVerita™—a benchtop treatment response monitoring device; and the OmniVerita™ M—a smartphone enabled portable device intended for cancer detection and infectious disease diagnostics.
Mr. Turner holds three patents with several pending in areas including the implementation of AC Electrokinetics for isolating nucleic acids, the design of non-biohazardous consumables, the integration of smartphones with AC electrokinetics and business methods for mobile diagnostics. He earned both an MEng and a BS in Bioengineering from UC San Diego.
